Placebo of Olmesartan

DRUG3 trials

Sponsors

Novartis Pharmaceuticals, Samsung Medical Center

Conditions

Coronary SyndromeEssential HypertensionHypertension

Phase 2

The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease

Samsung Medical CenterCoronary Syndrome

Start: 2015-08-31End: 2018-08-31Target: 504Updated: 2015-08-06

Phase 3

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension

CompletedNCT01785472

Novartis PharmaceuticalsEssential Hypertension

Start: 2013-04-30End: 2014-08-31Updated: 2016-12-29

Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan

CompletedNCT01876368

Novartis PharmaceuticalsHypertension

Start: 2013-09-30End: 2014-08-31Updated: 2015-12-07